MeSH term
Frequency | Condition_Probility | Adult | 77 | 0.0 |
Antihypertensive Agents/therapeutic use | 2 | 2.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Diabetes Mellitus, Type 2/*epidemiology/prevention & control | 2 | 7.0 |
*Diet, Reducing | 3 | 4.0 |
*Exercise | 2 | 1.0 |
Humans | 405 | 0.0 |
Incidence | 3 | 0.0 |
Male | 176 | 0.0 |
Middle Aged | 109 | 0.0 |
Reference Values | 27 | 0.0 |
Risk Factors | 6 | 0.0 |
Smoking/adverse effects | 2 | 0.0 |
*Smoking Cessation | 2 | 5.0 |
United States/epidemiology | 2 | 0.0 |
Weight Loss | 2 | 1.0 |
Animals | 177 | 0.0 |
Choline O-Acetyltransferase/genetics/*metabolism | 5 | 100.0 |
Research Support, Non-U.S. Gov't | 280 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Aged | 166 | 0.0 |
Cell Count | 10 | 1.0 |
Choline O-Acetyltransferase/*analysis | 27 | 96.0 |
Colon/*innervation | 3 | 23.0 |
Female | 157 | 0.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Dose-Response Relationship, Drug | 10 | 0.0 |
English Abstract | 12 | 0.0 |
Amino Acid Sequence | 16 | 0.0 |
Cell Line | 16 | 0.0 |
Choline O-Acetyltransferase/*chemistry/genetics/*metabolism | 2 | 100.0 |
Enzyme Activation | 2 | 0.0 |
In Vitro | 10 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Neurons/enzymology | 5 | 11.0 |
Phosphorylation | 4 | 0.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Acetylcholine/*metabolism | 15 | 48.0 |
Aged, 80 and over | 82 | 0.0 |
Biological Markers/chemistry | 2 | 11.0 |
Brain/metabolism | 4 | 0.0 |
Choline O-Acetyltransferase/metabolism | 93 | 63.0 |
Membrane Glycoproteins/metabolism | 3 | 0.0 |
*Membrane Transport Proteins | 17 | 2.0 |
*Neuropeptides | 2 | 1.0 |
Receptors, GABA-A/metabolism | 3 | 27.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 22 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 137 | 0.0 |
Supranuclear Palsy, Progressive/*metabolism | 2 | 50.0 |
Synaptic Vesicles/*metabolism | 2 | 16.0 |
*Vesicular Transport Proteins | 18 | 10.0 |
Age Factors | 11 | 0.0 |
Chronobiology/*physiology | 2 | 66.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Heart Rate/*physiology | 2 | 6.0 |
Time Factors | 14 | 0.0 |
Infant | 20 | 0.0 |
Phenotype | 7 | 0.0 |
Immunohistochemistry | 69 | 0.0 |
Neurons, Afferent/enzymology/ultrastructure | 2 | 100.0 |
Neurons, Efferent/physiology | 2 | 50.0 |
Synaptic Transmission/*physiology | 2 | 5.0 |
gamma-Aminobutyric Acid/metabolism | 4 | 12.0 |
Choline/*metabolism | 2 | 28.0 |
Comparative Study | 57 | 0.0 |
Hippocampus/*metabolism | 2 | 2.0 |
Mice | 41 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Alzheimer Disease/*metabolism/pathology | 6 | 6.0 |
Choline O-Acetyltransferase/*metabolism | 87 | 77.0 |
Cholinergic Fibers/enzymology/pathology | 2 | 100.0 |
Frontal Lobe/*enzymology/pathology | 2 | 66.0 |
Neuropsychological Tests | 9 | 3.0 |
Parietal Lobe/enzymology/pathology | 2 | 66.0 |
Temporal Lobe/enzymology/pathology | 2 | 66.0 |
Epithelial Cells/physiology | 2 | 2.0 |
Homeostasis | 2 | 0.0 |
Choline O-Acetyltransferase/analysis | 37 | 77.0 |
Cholinergic Fibers/*metabolism | 5 | 71.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
Models, Genetic | 2 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Child, Preschool | 19 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
*Questionnaires | 2 | 5.0 |
Reproducibility of Results | 3 | 0.0 |
Severity of Illness Index | 5 | 0.0 |
Adolescent | 21 | 0.0 |
Child | 25 | 0.0 |
Nerve Growth Factors/metabolism | 5 | 8.0 |
Neurotransmitters/metabolism | 4 | 11.0 |
Receptors, Neurotransmitter/metabolism | 2 | 11.0 |
*Chromosomal Proteins, Non-Histone | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Electroencephalography | 3 | 1.0 |
Infant, Newborn | 8 | 0.0 |
Neurons/metabolism/pathology | 2 | 2.0 |
*Repressor Proteins | 3 | 0.0 |
Hippocampus/enzymology/pathology/physiopathology | 2 | 100.0 |
Receptors, Dopamine/*metabolism | 3 | 37.0 |
Receptors, Dopamine D1/metabolism | 2 | 50.0 |
Drug Interactions | 3 | 0.0 |
Receptors, Nicotinic/drug effects | 2 | 28.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Autoradiography | 12 | 2.0 |
Choline O-Acetyltransferase/analysis/metabolism | 5 | 83.0 |
Cholinergic Fibers/chemistry/enzymology | 3 | 100.0 |
Postmortem Changes | 2 | 2.0 |
Rats | 100 | 0.0 |
Rats, Sprague-Dawley | 24 | 1.0 |
Tritium/diagnostic use | 2 | 1.0 |
Cell Survival/drug effects | 6 | 0.0 |
Cells, Cultured | 33 | 0.0 |
Disease Models, Animal | 13 | 0.0 |
*Nerve Growth Factors | 2 | 1.0 |
Nerve Tissue Proteins/*pharmacology | 4 | 4.0 |
Neuroprotective Agents/*pharmacology | 3 | 4.0 |
Pregnancy | 12 | 0.0 |
Spinal Cord/cytology | 3 | 21.0 |
Superoxide Dismutase/*genetics | 2 | 1.0 |
Gene Expression | 6 | 0.0 |
*Genetic Vectors | 2 | 0.0 |
Lentivirus/*genetics | 2 | 5.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Quinolinic Acid | 2 | 100.0 |
Rats, Wistar | 8 | 0.0 |
Biopsy | 2 | 0.0 |
Calcitonin Gene-Related Peptide/analysis | 2 | 2.0 |
Nitric-Oxide Synthase/analysis | 2 | 13.0 |
Substance P/analysis | 5 | 5.0 |
Autistic Disorder/*diagnosis | 3 | 100.0 |
Nicotine/pharmacology | 2 | 22.0 |
Physostigmine/pharmacology | 4 | 25.0 |
Clinical Trials | 3 | 0.0 |
Pan troglodytes/*virology | 2 | 66.0 |
*Poliovirus Vaccine, Oral | 6 | 75.0 |
SIV/physiology | 2 | 16.0 |
Kidney/*cytology/virology | 2 | 100.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Species Specificity | 11 | 0.0 |
Tissue Distribution | 13 | 0.0 |
Acetylcholinesterase/metabolism | 14 | 18.0 |
Alzheimer Disease/*metabolism | 23 | 11.0 |
Denervation | 2 | 5.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Glial Fibrillary Acidic Protein/analysis | 6 | 3.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Macaca mulatta | 7 | 1.0 |
Neurons/*chemistry/metabolism | 2 | 50.0 |
Receptors, Cholinergic/metabolism | 2 | 10.0 |
Signal Transduction | 2 | 0.0 |
Calcium/metabolism | 3 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Receptors, Cholinergic/physiology | 2 | 25.0 |
Chronic Disease | 4 | 0.0 |
Attention | 2 | 10.0 |
Cohort Studies | 4 | 0.0 |
Play and Playthings | 2 | 100.0 |
Sensitivity and Specificity | 2 | 0.0 |
Bungarotoxins/metabolism | 4 | 44.0 |
COS Cells | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Choline O-Acetyltransferase/biosynthesis/*genetics | 3 | 100.0 |
Kinetics | 12 | 0.0 |
Molecular Sequence Data | 30 | 0.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Swine | 9 | 0.0 |
Alzheimer Disease/enzymology | 2 | 13.0 |
Receptors, Cholinergic/*physiology | 3 | 33.0 |
Binding Sites | 7 | 0.0 |
Brain/*enzymology | 17 | 9.0 |
Receptors, Muscarinic/*metabolism | 9 | 24.0 |
Cell Transplantation | 2 | 2.0 |
Glutamate Decarboxylase/analysis | 3 | 37.0 |
Neurotransmitters/genetics/*metabolism | 2 | 100.0 |
Tyrosine 3-Monooxygenase/analysis | 5 | 6.0 |
Alzheimer Disease/*genetics | 2 | 0.0 |
Apolipoproteins E/*genetics | 4 | 0.0 |
Choline O-Acetyltransferase/*genetics | 20 | 95.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 10 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Psychiatric Status Rating Scales | 2 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Brain/*pathology | 4 | 2.0 |
Cholinergic Fibers/*pathology | 2 | 66.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
*Chronobiology | 2 | 50.0 |
In Situ Hybridization/methods | 2 | 1.0 |
Neurons/*enzymology | 7 | 10.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Motor Neurons/*enzymology | 2 | 33.0 |
Spinal Cord/*enzymology/pathology | 2 | 28.0 |
Blood Pressure/*physiology | 3 | 3.0 |
Hypertension/diagnosis | 2 | 28.0 |
Periodicity | 3 | 6.0 |
Aging/metabolism | 6 | 3.0 |
Brain/*drug effects/metabolism | 3 | 17.0 |
Cerebral Cortex/drug effects/metabolism | 2 | 22.0 |
Hemicholinium 3/metabolism | 2 | 100.0 |
Hippocampus/drug effects/metabolism | 2 | 16.0 |
Nicotine/*pharmacology | 2 | 7.0 |
Brain/pathology | 5 | 1.0 |
Neurons/*physiology | 3 | 2.0 |
Ornithine Carbamoyltransferase/*deficiency | 2 | 3.0 |
Prosencephalon/pathology/*physiopathology | 2 | 100.0 |
Choline O-Acetyltransferase/genetics | 6 | 60.0 |
Chromosome Mapping | 4 | 0.0 |
Avoidance Learning/drug effects | 2 | 25.0 |
Cognition | 2 | 3.0 |
Nerve Growth Factor/metabolism | 2 | 8.0 |
Frontal Lobe/enzymology/pathology | 2 | 50.0 |
Regression Analysis | 2 | 0.0 |
Communication | 3 | 15.0 |
*Internet | 2 | 20.0 |
Disease Progression | 6 | 0.0 |
Callithrix | 3 | 4.0 |
In Situ Hybridization | 9 | 0.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Acetylcholinesterase/*metabolism | 16 | 10.0 |
Blotting, Western | 8 | 0.0 |
Hand Strength/physiology | 2 | 18.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Mice, Neurologic Mutants | 2 | 1.0 |
Organ Size | 3 | 1.0 |
Aging | 3 | 0.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Alleles | 6 | 0.0 |
Autopsy | 6 | 3.0 |
Cholinergic Fibers/enzymology/*pathology | 3 | 60.0 |
Predictive Value of Tests | 2 | 0.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
Acetylcholine/secretion | 2 | 66.0 |
Base Sequence | 22 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
PC12 Cells | 6 | 1.0 |
*Transfection | 2 | 0.0 |
Acetylcholinesterase/analysis | 6 | 17.0 |
Microscopy, Confocal | 4 | 0.0 |
Cholinergic Fibers/enzymology | 5 | 71.0 |
Brain Chemistry | 5 | 1.0 |
*Gene Expression Regulation | 3 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Injections, Intraventricular | 3 | 2.0 |
Plasmids | 2 | 0.0 |
Brain-Derived Neurotrophic Factor/pharmacology | 2 | 4.0 |
Models, Neurological | 2 | 1.0 |
Nerve Degeneration | 3 | 4.0 |
Nerve Growth Factors/*pharmacology/physiology | 2 | 50.0 |
Nerve Tissue Proteins/pharmacology | 5 | 11.0 |
Organ Culture Techniques | 5 | 1.0 |
Calcitonin Gene-Related Peptide/metabolism | 3 | 8.0 |
Calcium-Binding Protein, Vitamin D-Dependent/analysis | 2 | 14.0 |
Histocytochemistry | 19 | 2.0 |
NADPH Dehydrogenase/analysis | 3 | 20.0 |
Parvalbumins/analysis | 3 | 42.0 |
Acetylcholine/metabolism | 9 | 30.0 |
Neurons/physiology | 2 | 1.0 |
Calcium-Binding Protein, Vitamin D-Dependent/*metabolism | 3 | 42.0 |
Chickens | 4 | 0.0 |
Neurons/*metabolism | 5 | 1.0 |
Alzheimer Disease/enzymology/pathology | 3 | 42.0 |
Cerebral Cortex/enzymology/pathology | 3 | 42.0 |
Lewy Bodies/*pathology | 2 | 33.0 |
Neurons/pathology | 3 | 2.0 |
Biological Markers | 13 | 0.0 |
Nerve Tissue Proteins/*analysis | 5 | 6.0 |
Cattle | 9 | 0.0 |
Haplorhini | 2 | 0.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
Spinal Cord/cytology/metabolism | 2 | 13.0 |
Alzheimer Disease/metabolism | 5 | 7.0 |
Binding Sites/physiology | 3 | 1.0 |
Frontal Lobe/metabolism | 3 | 10.0 |
Parkinson Disease/*metabolism | 4 | 14.0 |
Quinuclidinyl Benzilate/metabolism | 10 | 90.0 |
Temporal Lobe/metabolism | 4 | 25.0 |
Transfection | 13 | 0.0 |
Acetylcholine/physiology | 3 | 30.0 |
Brain/*physiopathology | 4 | 9.0 |
Cholinesterase Inhibitors/therapeutic use | 2 | 18.0 |
Acetylcholine/*biosynthesis | 4 | 66.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Okadaic Acid/pharmacology | 2 | 2.0 |
Age of Onset | 3 | 0.0 |
Apolipoproteins E/genetics/*physiology | 2 | 8.0 |
Brain/enzymology/pathology | 2 | 18.0 |
Gene Frequency | 2 | 0.0 |
Nerve Tissue Proteins/analysis | 9 | 12.0 |
Single-Blind Method | 3 | 1.0 |
Blood Pressure/physiology | 2 | 1.0 |
Circadian Rhythm | 2 | 0.0 |
Heart Rate/physiology | 2 | 2.0 |
Cerebral Cortex/*enzymology | 5 | 45.0 |
Brain/*enzymology/pathology | 3 | 18.0 |
Organ Specificity | 8 | 0.0 |
Culture Media | 2 | 0.0 |
Neurons/cytology/enzymology | 2 | 33.0 |
Cadaver | 2 | 0.0 |
Nerve Tissue Proteins/metabolism | 5 | 2.0 |
Brain/metabolism/pathology | 5 | 4.0 |
Receptors, Nicotinic/*metabolism | 4 | 57.0 |
Synapses/ultrastructure | 2 | 40.0 |
Synaptophysin/metabolism | 4 | 12.0 |
Ciliary Neurotrophic Factor | 11 | 9.0 |
Embryo | 3 | 0.0 |
Recombinant Proteins/pharmacology | 8 | 0.0 |
Chick Embryo | 2 | 0.0 |
RNA, Antisense | 2 | 3.0 |
Sequence Alignment | 2 | 0.0 |
Paraffin Embedding | 2 | 0.0 |
Brain/cytology/*metabolism | 2 | 4.0 |
Neurons/metabolism | 6 | 1.0 |
Choline O-Acetyltransferase/analysis/*metabolism | 4 | 100.0 |
Perfusion | 2 | 0.0 |
Brain Chemistry/*drug effects | 2 | 12.0 |
Choline O-Acetyltransferase/drug effects/metabolism | 2 | 100.0 |
Synaptic Vesicles/metabolism | 3 | 18.0 |
Transcription, Genetic | 7 | 0.0 |
Biogenic Monoamines/metabolism | 2 | 25.0 |
Body Weight/drug effects | 2 | 1.0 |
*Nerve Degeneration | 2 | 8.0 |
Nerve Growth Factors/*pharmacology | 15 | 12.0 |
Rats, Inbred F344 | 5 | 1.0 |
Cats | 6 | 1.0 |
Drug Delivery Systems | 2 | 2.0 |
Hamsters | 5 | 0.0 |
Polymers | 2 | 1.0 |
Radioimmunoassay | 8 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Choline O-Acetyltransferase/*antagonists & inhibitors | 2 | 100.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Nerve Growth Factors/*metabolism | 2 | 2.0 |
Neurotrophin 3 | 4 | 4.0 |
Brain/*metabolism | 6 | 1.0 |
Carrier Proteins/*biosynthesis/*genetics | 2 | 8.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Muscle, Smooth/*innervation | 2 | 28.0 |
*Nervous System Physiology | 2 | 8.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Choline O-Acetyltransferase/*biosynthesis/genetics | 2 | 100.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Brain/enzymology | 7 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Immune Sera/*immunology | 2 | 8.0 |
Immunoblotting | 4 | 0.0 |
Placenta/enzymology | 4 | 5.0 |
Choline O-Acetyltransferase/*immunology | 6 | 100.0 |
Guinea Pigs | 5 | 0.0 |
Choline O-Acetyltransferase/*drug effects | 2 | 100.0 |
Epithelial Cells | 2 | 0.0 |
Neurons/chemistry/enzymology | 2 | 28.0 |
Aging/*metabolism | 8 | 3.0 |
Receptors, Nerve Growth Factor/*metabolism | 3 | 6.0 |
Substantia Innominata/*metabolism | 2 | 100.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Microscopy, Electron | 7 | 0.0 |
Brain Chemistry/physiology | 2 | 7.0 |
Motor Neurons/*metabolism | 2 | 9.0 |
Capsules | 3 | 6.0 |
Kidney/cytology | 2 | 1.0 |
Acetylcholine/biosynthesis | 4 | 80.0 |
Behavior, Animal | 2 | 2.0 |
Neuropeptide Y/analysis | 2 | 2.0 |
Norepinephrine/analysis | 3 | 17.0 |
Staining and Labeling | 4 | 0.0 |
CHO Cells | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Molecular Weight | 9 | 0.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
Aging/*metabolism/pathology | 2 | 28.0 |
Brain/*metabolism/pathology | 5 | 6.0 |
Case-Control Studies | 4 | 0.0 |
Down Syndrome/*metabolism/pathology | 2 | 33.0 |
Neurofibrillary Tangles/*pathology | 2 | 9.0 |
Neuropsychological Tests/statistics & numerical data | 2 | 11.0 |
Blotting, Northern | 9 | 0.0 |
*Gene Therapy | 2 | 0.0 |
Cerebral Cortex/metabolism | 5 | 7.0 |
Hippocampus/metabolism | 2 | 2.0 |
Interneurons/*metabolism | 2 | 40.0 |
Neuropeptides/analysis | 2 | 10.0 |
*Cognition | 2 | 4.0 |
Amyotrophic Lateral Sclerosis/*pathology | 2 | 14.0 |
Butyric Acid | 3 | 6.0 |
Butyric Acids/*pharmacology | 3 | 13.0 |
Neurotransmitters/physiology | 2 | 6.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Acetylcholinesterase/analysis/metabolism | 2 | 33.0 |
Dogs | 2 | 0.0 |
Brain-Derived Neurotrophic Factor | 6 | 6.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Phosphopyruvate Hydratase/analysis/metabolism | 2 | 100.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Alzheimer Disease/metabolism/*pathology | 8 | 25.0 |
Neurons/metabolism/*pathology | 3 | 10.0 |
Temporal Lobe/enzymology/*metabolism | 2 | 100.0 |
Hippocampus/enzymology/metabolism | 2 | 100.0 |
Cholinesterase Inhibitors/pharmacology | 3 | 7.0 |
Choline O-Acetyltransferase/*analysis/immunology | 2 | 100.0 |
Motor Neurons/chemistry/enzymology | 2 | 100.0 |
Rabbits | 5 | 0.0 |
Astrocytes/metabolism | 2 | 2.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Brain/enzymology/metabolism/*pathology | 2 | 100.0 |
Neurofibrillary Tangles/pathology | 3 | 5.0 |
*Genes | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Parasympathetic Nervous System/*cytology/drug effects/enzymology | 2 | 100.0 |
Tretinoin/*pharmacology | 4 | 1.0 |
Mice, Mutant Strains | 2 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Neurites/physiology | 2 | 10.0 |
Neurons/*drug effects | 2 | 5.0 |
Oligonucleotide Probes | 3 | 0.0 |
*Chromosomes, Human, Pair 10 | 2 | 1.0 |
Dopamine/*metabolism | 3 | 2.0 |
Homovanillic Acid/metabolism | 2 | 12.0 |
Hydroxyindoleacetic Acid/metabolism | 2 | 14.0 |
Serotonin/*metabolism | 3 | 6.0 |
Animals, Newborn | 3 | 0.0 |
Drug Synergism | 4 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Acetylcholine/*physiology | 3 | 16.0 |
Neural Pathways | 2 | 11.0 |
Synaptic Transmission | 4 | 10.0 |
Alzheimer Disease/*enzymology/*genetics | 2 | 50.0 |
Alternative Splicing | 2 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Neurotransmitters/*analysis | 6 | 35.0 |
DNA, Complementary | 3 | 0.0 |
Muscles/cytology | 2 | 10.0 |
Parasympathetic Nervous System/cytology | 2 | 100.0 |
Fluorescent Dyes | 2 | 0.0 |
Glutamate Decarboxylase/metabolism | 4 | 23.0 |
Prosencephalon/cytology/*physiology | 2 | 40.0 |
Neuroblastoma | 5 | 2.0 |
Introns | 2 | 0.0 |
Brain/enzymology/*pathology | 3 | 42.0 |
Neurons/enzymology/*pathology | 3 | 75.0 |
Alzheimer Disease/*pathology | 5 | 9.0 |
Brain Stem/enzymology/pathology | 2 | 50.0 |
Silver Staining | 3 | 3.0 |
DNA Probes | 2 | 0.0 |
Parasympathetic Nervous System/*metabolism | 3 | 50.0 |
Tyrosine 3-Monooxygenase/metabolism | 4 | 2.0 |
Schizophrenia/enzymology | 2 | 28.0 |
Research | 2 | 3.0 |
gamma-Aminobutyric Acid/analysis | 5 | 45.0 |
*Benzeneacetamides | 2 | 25.0 |
Binding, Competitive | 4 | 0.0 |
Exons | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/*physiology | 2 | 2.0 |
Alzheimer Disease/enzymology/*metabolism/pathology | 4 | 66.0 |
Genes, Structural | 2 | 0.0 |
Cholinergic Fibers/metabolism/*pathology | 2 | 100.0 |
Parasympathetic Nervous System/metabolism/*pathology | 3 | 60.0 |
Alzheimer Disease/*enzymology/pathology | 4 | 13.0 |
*Brain Chemistry | 10 | 5.0 |
Brain/growth & development/*metabolism | 2 | 7.0 |
Fetus | 4 | 0.0 |
Neurotransmitters/*metabolism | 6 | 20.0 |
Cerebral Cortex/*metabolism | 8 | 15.0 |
Corpus Striatum/*metabolism | 3 | 15.0 |
Somatostatin/*metabolism | 4 | 17.0 |
Alcoholism/*metabolism | 2 | 25.0 |
Restriction Mapping | 2 | 0.0 |
Receptors, Glutamate/*metabolism | 2 | 33.0 |
Receptors, Neurotransmitter/*metabolism | 3 | 10.0 |
Corpus Striatum/*metabolism/pathology | 2 | 25.0 |
Putamen/metabolism | 5 | 38.0 |
Tritium | 2 | 0.0 |
Acetylcholinesterase/immunology/metabolism | 2 | 66.0 |
Choline O-Acetyltransferase/immunology/metabolism | 2 | 100.0 |
Tissue Fixation | 2 | 2.0 |
Iodine Radioisotopes/diagnostic use | 3 | 0.0 |
Neuropeptide Y/metabolism | 6 | 9.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Neurons/cytology/drug effects | 2 | 18.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Sheep | 2 | 0.0 |
Torpedo | 2 | 5.0 |
Antibodies, Monoclonal/immunology | 4 | 0.0 |
Atrophy | 2 | 1.0 |
Hippocampus/*chemistry | 2 | 11.0 |
Receptors, Nerve Growth Factor/*analysis | 3 | 20.0 |
Risk | 2 | 0.0 |
Choline/metabolism | 5 | 13.0 |
Acetylcholinesterase/*analysis | 7 | 12.0 |
Amyotrophic Lateral Sclerosis/*enzymology | 2 | 15.0 |
RNA Probes | 2 | 1.0 |
Spinal Cord/*enzymology | 5 | 55.0 |
DNA/genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Child Language | 3 | 100.0 |
Dopamine/metabolism | 4 | 3.0 |
Serotonin/metabolism | 5 | 6.0 |
Basal Ganglia/*pathology | 2 | 33.0 |
Rats, Inbred Strains | 13 | 1.0 |
Hippocampus/chemistry | 2 | 18.0 |
Dopamine/analysis | 2 | 13.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Neurons/cytology | 2 | 4.0 |
Receptors, Cholinergic/*analysis | 2 | 66.0 |
Receptors, Muscarinic/*analysis | 5 | 45.0 |
Caudate Nucleus/metabolism | 4 | 36.0 |
Spiperone/metabolism | 3 | 27.0 |
Substance P/metabolism | 3 | 5.0 |
Vasoactive Intestinal Peptide/metabolism | 2 | 2.0 |
Neurons/cytology/metabolism | 2 | 2.0 |
Receptors, Cell Surface/*metabolism | 3 | 0.0 |
Receptors, Nerve Growth Factor | 4 | 8.0 |
Glutamates/analysis | 3 | 42.0 |
Glutamic Acid | 4 | 5.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Substantia Nigra/pathology | 2 | 20.0 |
Glucose/*metabolism | 2 | 1.0 |
Tomography, Emission-Computed | 2 | 1.0 |
Corpus Striatum/*drug effects/metabolism | 2 | 66.0 |
Amygdala/metabolism | 3 | 33.0 |
Neurofilament Proteins | 2 | 9.0 |
Neuromuscular Diseases/*physiopathology | 2 | 100.0 |
Tissue Extracts/*pharmacology | 2 | 8.0 |
Substance P/*metabolism | 3 | 10.0 |
Cholinesterases/metabolism | 2 | 18.0 |
Membrane Transport Proteins/metabolism | 2 | 11.0 |
Receptors, Muscarinic/metabolism | 3 | 12.0 |
Database Management Systems | 2 | 40.0 |
*Information Systems | 2 | 20.0 |
*Language Development | 2 | 100.0 |
Glutamates/*metabolism | 2 | 20.0 |
gamma-Aminobutyric Acid/*metabolism | 4 | 21.0 |
Blood Pressure Monitoring, Ambulatory | 2 | 4.0 |
Circadian Rhythm/*physiology | 2 | 2.0 |
Ethanol/*toxicity | 2 | 6.0 |
Cytarabine/pharmacology | 2 | 4.0 |
DNA Replication/drug effects | 2 | 1.0 |
Glutaminase/*metabolism | 2 | 100.0 |
Brain/drug effects/*enzymology | 2 | 18.0 |
Synaptosomes/drug effects/*enzymology | 2 | 100.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Great Britain | 3 | 1.0 |
Retrospective Studies | 2 | 0.0 |
Choline O-Acetyltransferase/cerebrospinal fluid | 2 | 100.0 |
Butyrates/*pharmacology | 2 | 4.0 |
*Neuroblastoma | 3 | 15.0 |
Tumor Cells, Cultured/drug effects/*enzymology | 2 | 40.0 |
Alzheimer Disease/*enzymology | 15 | 31.0 |
Receptors, GABA-A/*metabolism | 3 | 10.0 |
Norepinephrine/metabolism | 3 | 6.0 |
Aspartic Acid/analysis | 2 | 33.0 |
Somatostatin/analysis | 2 | 3.0 |
Neurofibrils/pathology | 3 | 25.0 |
Parasympathetic Nervous System/*physiopathology | 2 | 50.0 |
Dementia/*enzymology | 7 | 70.0 |
Brain Mapping | 3 | 2.0 |
Dementia/*metabolism | 6 | 35.0 |
Basal Ganglia/*enzymology | 2 | 66.0 |
Alzheimer Disease/enzymology/*pathology | 3 | 60.0 |
Cerebral Cortex/enzymology | 5 | 23.0 |
Macromolecular Substances | 2 | 0.0 |
Substantia Innominata/enzymology | 2 | 50.0 |
Amygdala/enzymology | 2 | 33.0 |
Hippocampus/enzymology | 5 | 23.0 |
Somatostatin/metabolism | 2 | 4.0 |
Brain/enzymology/*metabolism | 2 | 14.0 |
Receptors, Cholinergic/*metabolism | 2 | 11.0 |
Catecholamines/metabolism | 2 | 4.0 |
Down Syndrome/*metabolism | 3 | 14.0 |
Cholinergic Fibers | 4 | 80.0 |
Norepinephrine/*metabolism | 2 | 5.0 |
Dementia/enzymology/*pathology | 2 | 100.0 |
2',3'-Cyclic-Nucleotide Phosphodiesterases/metabolism | 2 | 22.0 |
Globus Pallidus/enzymology | 3 | 60.0 |
Caudate Nucleus/enzymology | 2 | 22.0 |
Putamen/enzymology | 3 | 37.0 |
Hippocampus/*analysis/enzymology | 2 | 100.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Choline O-Acetyltransferase/*blood | 2 | 100.0 |
*Circadian Rhythm | 2 | 0.0 |
Nicotinic Agonists/pharmacology | 2 | 25.0 |
Neurons/*pathology | 2 | 3.0 |
*Antibody Formation | 3 | 3.0 |
Poliomyelitis/*immunology | 3 | 75.0 |
*Poliovirus Vaccine, Inactivated | 3 | 100.0 |
Sweden | 4 | 1.0 |
*Vaccination | 3 | 5.0 |
